Brought to you by 
Amgen gets rights to Progenitor's leptin receptor technology
13 Jul 1999
Executive Summary
Amgen acquired exclusive worldwide rights to develop and commercialize Interneuron subsidiary Progenitor's leptin receptor technology for therapeutic, diagnostic and prophylactic uses.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amgen gets rights to Progenitor's leptin receptor technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice